Sam, who are you holding immunotherapy for? Are you using PD-L1 score here in HER2-driven disease? Can you briefly touch on the data in your practice since the approval of Zanny?

So very cool drug.

We're going to see more drugs like this, in my opinion, that sort of better biologic targeting of HER2 with this trans binding biparatopic mechanism.

It's quite cool.

And anyone interested, you know, I encourage you to take a dive because it's a very cool way of coming at a target.

But essentially, they went head to head against the standard when the trial was designed, which was trastuzumab-based chemotherapy combination.

It's a very clean comparison and it is a very clear win.

Sam, can you touch on these limited options here? And when you are using Paclitaxel, Ramicirumab, are you using Paclitaxel on day 1, 8, 15, and Ramicirumab day 1 and 15, as it was initially proved? Or do you also switch your Paclitaxel day 1 and day 15?

[laughs]

Uh, here are my disclosures So I was asked to talk about some perioperative updates, picking out these subgroups that, that Neil just touched on, a little bit about the frontline checkpoint landscape, uh, and then some claudin, uh, therapies.

So as Yelena mentioned, you know, it used to be a debate of carboplatin radiation, perioperative chemotherapy, et cetera, but now after Matterhorn, which I agree is probably one of the papers of the year, it's really become much more simple clinically for us.

If a patient is operable, this is the preferred approach.

This is why we saw this data at ESMO, and this data is soon to be published, but why do we change practice? Because we have therapies that are now improving event-free survival, which we saw and is published, and now overall survival.

So I'm, I'm a simple person.

I think, you know, we can now tell people that the overall survival at two years, three-quarters of patients are alive, a little more than two-thirds at three years, and certainly we'll wait to see long-term follow-up, uh, from Matterhorn, which will be important to sort of define that five-year cure rate, which is what we want to be able to tell patients.

I don't think so.